Active, not recruitingPhase 2NCT03793140

A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

Studying Burkitt lymphoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigator: Ariela Noy, MD
Memorial Sloan Kettering Cancer Center
Intervention: CPI-613(drug)
Enrollment: 24 target
Eligibility: 12 years · All sexes
Timeline: 2018 – 2026

Study locations (11)

City of Hope, Duarte, California, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Memorial Sloan Kettering Commack, Commack, New York, United States
Memorial Sloan Kettering Westchester, Harrison, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Memorial Sloan Kettering Nassau, Uniondale, New York, United States
University of Pennsylvania (Data Collection Only), Philadelphia, Pennsylvania, United States
Md Anderson Cancer Center, Houston, Texas, United States

Collaborators

City of Hope Medical Center · Massachusetts General Hospital · M.D. Anderson Cancer Center · George Washington University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03793140 on ClinicalTrials.gov

Other trials for Burkitt lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Burkitt lymphoma →

← Back to all trials